The new stock repurchase program may signal a lack of ... Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system ...

The latest update is out from Ashtead ( (GB:AHT) ).

Qifu Technology said its board of directors approved a new share buyback plan to purchase up to $450 million of American Depositary Shares or Class A ordinary shares. The credit-tech platform in China ...

Under the buyback plan, BY will be able to repurchase up to 1.25 million shares, representing roughly 2.8% of its existing outstanding common stock. The repurchase plan will be in effect from Jan ...

In addition, documents specifying the terms, conditions and procedures for exercising the Repurchase Right will be available through the Depository Trust Company and the paying agent, which is The ...

The Company launched a $250.0 million stock repurchase program with respect to the Common Stock (the "Stock Repurchase Program”). Under the terms of the Company's Convertible Note Purchase Agreement ...

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase program for up to an additional aggregate ...

Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock repurchase ...